Aurobindo Pharma rises on hopes of strong Q2 earnings

The stock has rallied 56% in past two months from Rs 102 on August 10, as compared to 7% rise in benchmark Sensex

Aurobindo Pharma is trading higher by over 4% to Rs 159, also its 52-week high, on the Bombay Stock Exchange on expectation of healthy revenue growth in coming quarters. The stock of pharmaceutical company has rallied 56% in past two months from Rs 102 on August 10, as compared to 7% rise in benchmark Sensex.

Analyst at India Nivesh expects that the company is likely to report healthy revenue growth of above 20% from US on the back of 8-9 ANDA approvals from US Food and Drug Administration's (USFDA).

“Aurobindo Pharma is expected to post a net sales growth of 25.5% year-on-year, led by formulation exports for the second quarter ended September 2012,” Angel Broking said in Q2 results preview.

 

The margins are likely to expand to 15.1% vs 10.7% (in 2QFY2012), which will lead to a net profit of Rs 48.40 crore vs a net loss of Rs 80.20 crore, said report.

The stock opened at Rs 152 and has seen a combined 3.02 million shares changing hands on the counter so far on both the exchanges.